Take a look back at a handful of groundbreaking research discoveries that marked one of, if not the most, unprecedented and transformative years for Feinberg.
A novel antibiotic drug showed similar treatment effectiveness compared to current therapies in patients with antibiotic resistant bacterial infections, according to two complementary clinical trials.
The presence of inflammatory proteins was associated with comorbidity burden and deteriorating heart function in patients with heart failure with preserved ejection fraction, according to a Northwestern Medicine study.
The Northwestern University Clinical and Translational Sciences (NUCATS) Institute hosted the first virtual COVID-19 symposium, which gave the Northwestern research community an opportunity to learn about efforts to advance public health and respond to the COVID-19 pandemic.
Feinberg principal investigators secured a record-breaking $643 million in research funding and awards during the 2019-2020 fiscal year.
At Northwestern Medicine, various COVID-19 antibody testing efforts have been underway since the beginning of the pandemic.
A novel heart failure drug called sacubitril-valsartan reduced the risk of hospitalizations for heart failure and death from cardiovascular causes more in women than in men, according to a study published in Circulation.
Risk of relapse for chronic myeloid leukemia patients may be reduced through drug combination after discontinuing initial therapy, according to a Northwestern Medicine study published in the journal Leukemia.
Elagolix, a newly developed orally administered drug, was effective in reducing heavy menstrual bleeding in women with uterine fibroids, according to a recent Northwestern Medicine clinical trial.